Cipla Limited FDA-483

FDA has released the FDA-483 issued following a 9/24-9/28 inspection at Cipla Limited, a Goa, India, drug manufacturer. The two inspection observations were: 

  •          batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing; and
  •          written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.

Read more